- Home
- VOYA vs SYRE Comparison
VOYA vs SYRE Comparison
Compare VOYA & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VOYA | SYRE |
|---|---|---|
| Founded | 1975 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 8.5B |
| IPO Year | 2012 | 2015 |
Fundamental Metrics
Financial Performance| Metric | VOYA | SYRE |
|---|---|---|
| Price | $103.41 | $90.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $84.90 | ★ $85.08 |
| AVG Volume (30 Days) | 778.0K | ★ 1.0M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | ★ 1.94 | N/A |
| EPS | ★ 2.73 | N/A |
| Revenue | ★ $8,189,000,000.00 | N/A |
| Revenue This Year | $3.13 | N/A |
| Revenue Next Year | $3.93 | N/A |
| P/E Ratio | $37.41 | ★ N/A |
| Revenue Growth | ★ 1.73 | N/A |
| 52 Week Low | $64.50 | $14.51 |
| 52 Week High | $105.64 | $110.18 |
Technical Indicators
Market Signals| Indicator | VOYA | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 37.78 |
| Support Level | $97.08 | $82.83 |
| Resistance Level | $103.45 | $106.10 |
| Average True Range (ATR) | 2.07 | 4.23 |
| MACD | 0.07 | -1.29 |
| Stochastic Oscillator | 68.62 | 15.03 |
Price Performance
Historical ComparisonAbout VOYA Voya Financial Inc.
Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Retirement, Investment Management and Employee Benefits.The majority revenue is from Retirement segment.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.